(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 278.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Renovorx's revenue in 2026 is $928,000.On average, 6 Wall Street analysts forecast RNXT's revenue for 2026 to be $155,908,743, with the lowest RNXT revenue forecast at $108,960,200, and the highest RNXT revenue forecast at $198,056,146. On average, 5 Wall Street analysts forecast RNXT's revenue for 2027 to be $612,493,396, with the lowest RNXT revenue forecast at $287,335,341, and the highest RNXT revenue forecast at $1,068,564,951.
In 2028, RNXT is forecast to generate $1,997,237,172 in revenue, with the lowest revenue forecast at $794,386,929 and the highest revenue forecast at $3,559,513,142.